<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400686</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-5497</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-5497</secondary_id>
    <secondary_id>ORTHO-CASE-CCF-5497</secondary_id>
    <nct_id>NCT00400686</nct_id>
  </id_info>
  <brief_title>Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma</brief_title>
  <official_title>A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat
      anemia in patients with multiple myeloma.

      PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in
      patients undergoing chemotherapy for multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the hematologic response and transfusion requirements of chemotherapy-related
           moderate anemia to the administration of a high initial dose of epoetin alfa followed by
           a less frequent maintenance dose of epoetin alfa in multiple myeloma patients.

      Secondary

        -  Determine the effect of moderate anemia on quality of life in these patients.

        -  Correlate changes in hemoglobin levels with changes in quality of life in patients
           treated with this drug.

        -  Determine the effect of this drug on transfusion requirements after day 28 in these
           patients.

      OUTLINE: This is an open-label, non-randomized, pilot study.

      Patients receive high-dose epoetin alfa subcutaneously (SC) once a week for 4 weeks or until
      their hemoglobin levels reach 12-13 g/dL. Patients then receive epoetin alfa SC once every 2
      weeks for 8 weeks OR once a week for 4 weeks, and then once every 2 weeks for 8 weeks (as
      long as their hemoglobin levels remain between 12-13 g/dL). Patients then receive maintenance
      epoetin alfa SC once every 4 weeks for up to 12 weeks.

      Patients whose hemoglobin level decreases by 1-1.5 g/dL return to previous epoetin alfa
      schedule. Patients whose hemoglobin level is &lt; 9 g/dL after returning to the previous
      schedule may receive epoetin alfa for an additional 24 weeks.

      Quality of life is assessed at baseline and at weeks 2, 4, 8, 16, and 24 weeks during
      treatment.

      After completion of study treatment, patients are followed periodically for survival.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin at Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an at Least 1gm/dL Increase in Hgb</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an at Least 2gm/dL Increase in Hgb</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Anemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Epoetin Alfa - 80,000 U sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <description>Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
    <arm_group_label>Epoetin Alfa - 80,000 U sc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed multiple myeloma (MM)

          -  Requiring active therapy for MM

               -  Planning to undergo chemotherapy for ≥ 3 months

          -  Moderate anemia caused by MM and/or chemotherapy, as evidenced by hemoglobin ≤ 11.0
             g/dL

          -  No untreated anemia predominantly due to factors other than MM/chemotherapy (i.e.,
             iron or folate deficiencies, hemolysis, HIV, or gastrointestinal bleeding)

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          -  Life expectancy ≥ 6 months

          -  Transferrin saturation ≥ 20%

          -  Ferritin ≥ 100 ng/mL

          -  Homocysteine normal (concurrent vitamin supplementation allowed)

          -  Methylmalonic acid normal (concurrent vitamin supplementation allowed)

          -  Renal function normal

          -  No uncontrolled hypertension

          -  No prior thrombotic events unless treated with appropriate prophylaxis

          -  No known hypersensitivity to mammalian cell-derived products

          -  No uncontrolled infection

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Weight &lt; 100 Kg

          -  Patients with iron, folate, or vitamin B_12 deficiency allowed provided conditions are
             corrected prior to study entry

          -  Able to read and understand English at a 7th grade level

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior total lymphoid, extensive abdominal, or inverted Y radiotherapy

          -  Concurrent red blood cell transfusion allowed provided hemoglobin ≤ 7 g/dL AND patient
             is symptomatic

          -  Concurrent vitamin supplementation allowed for cyanocobalamin (vitamin B_12) or folate
             deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Sobecks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>June 3, 2015</results_first_submitted>
  <results_first_submitted_qc>October 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 9/2003 to 6/2008, a total of 31 patients were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" lower_limit="41" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin at Day 28</title>
        <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Day 28</title>
          <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-3.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an at Least 1gm/dL Increase in Hgb</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an at Least 1gm/dL Increase in Hgb</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an at Least 2gm/dL Increase in Hgb</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an at Least 2gm/dL Increase in Hgb</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data highlights development of VTEs in patients receiving one of the following: 1. lenalidomide, high dose dexamethasone &amp; Aspirin 325mg daily 2. thalidomide &amp; doxil based therapy with aspirin 81mg daily 3. cyclophosphamide &amp; prednisone without VTE</time_frame>
      <desc>Only immediately reportable Serious Adverse Events (SAE) &amp; Venous thrombolytic event (VTE) were captured for the purpose of this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Thromboembolic Event (VTE)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Faiman, MSN,CNP, AOCN</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-3738</phone>
      <email>faimanb@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

